Analysis of the top 50 global pharmaceutical companies in 2015: How far is the Chinese pharmaceutical company's dream from the top 50?

In 2014, the king of prescription drug sales did not have any suspense, and Novartis was re-elected; the list and the flowers did not move, and Pfizer and Roche followed. In the annual ranking competition, this year we are more involved. The 50th Japan Concord prescription drug sales are about 13.3 billion yuan, which is for Chinese pharmaceutical companies interested in growing into an international company. It is a threshold that is not so far away, and some pharmaceutical companies have even crossed.

Three major factors affect ranking

For the latest list in 2015, what is the main point of our attention is what causes the change in rankings? What are the key words of the big guys? Specialist drug sales, record-breaking M&A and global expansion for tax cuts are the top 10 keywords for this year's list. At the same time, this is also an important feature of the ranks of soaring pharmaceutical companies.

It must be mentioned inevitably - Gilead has madly made two consecutive years. Led by the breakthrough results of hepatitis C drugs, Gilead Sciences recorded a global sales of $24.5 billion in prescription drugs in 2014, and its ranking jumped from 18 last year to the top 10 this year, ranking 9th. . This fully demonstrates the opportunities for rapid development of specialty medicines, especially in areas where medical needs are highly unmet.

Another fast-growing company is Actavis, which rose from 24th to 19th this year. Atvis has always pursued an opportunistic strategy through mergers and acquisitions. Earlier this year, the company completed a $66 billion acquisition of Allergan. After combining Ai Jian's business, Artes is expected to hit the top 10 in the next year.

Analysis of the top 50 global pharmaceutical companies in 2015: How far is the Chinese pharmaceutical company's dream from the top 50?

Table: Top 50 list of global prescription drug companies in 2014

Last year, the FDA approved 41 new drugs, and the market is generally optimistic about the growth potential of the biopharmaceutical industry. Cutting-edge scientific research has made the product line under development increasingly rich, and more and more patients will benefit from it. According to the 18th Annual Global CEO Survey released by PricewaterhouseCoopers earlier, 92% of CEOs of pharmaceutical and life sciences companies said they are confident in the company's revenue growth in the next three years. Moreover, 58% of the CEOs surveyed hope to increase their staff in the coming year.

In addition, emerging markets are increasingly important to large pharmaceutical companies. Joaquin Duato, chairman of Johnson & Johnson Pharmaceuticals Global, said: "We are cautiously optimistic about the global economy. Emerging markets are a very important driver of growth, but at the same time, the US, Japan and European economies are still performing well. It is the cornerstone of our growth."

Aside from macroeconomics, it is not a simple matter for a high-risk R&D company to achieve sustained growth and to continually optimize costs to achieve commercial benefits. Whether growth is organic, from new drug discovery, development, listing, post-marketing management, or through mergers, acquisitions, and licensing transactions, to sustain growth, a series of issues must be resolved and continued. Talent is the most valuable intangible asset.

External acquisition or research and development

Growth needs change, and the ability to detect, develop, and support new businesses is acute. Regardless of the company's decision making, seeking acquisition targets, preparing for new drug launches, opening up new markets, or cutting costs, any restructuring process is an opportunity to realign talent and business.

Transmission Hardware Fitting

Socket Eyes are used for connecting conductor clamping devices to ball and socket type insulators. Made by malleable iron, hot dip galvanized to meet ASTM A153 specification.

Ball Eyes are used to attach ball and socket insulators to other associated hardware. Hot dip galvanized to meet ASTM A153 specification.

Thimble Cleivs are used for attaching guy to pole eye plate. Hot dip galvanized to meet ASTM A153 specification.

Turnbuckles are used as adjustable extension links to maintain proper tower clearance on assemblies at tower end.

Strain Clamp used for distribution and transmission line construction with all aluminum ACSR, or aluminum alloy conductor.


Transmission Hardware Fitting,Power Line Fitting,Wire Rope Thimble Clevis,Hot Line Socket Clevises

Ningbo Yokelink Machinery Co.,Limited , https://www.yokelink.com

Posted on